Single and Multiple Ascending Dose Study With EP395

  • STATUS
    Recruiting
  • days left to enroll
    2
  • participants needed
    78
  • sponsor
    EpiEndo Pharmaceuticals
Updated on 6 May 2021

Summary

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development

Description

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development. The study consists of two parts, part A where single-ascending doses will be assessed and part B where multiple-ascending doses will be assessed. The primary objective being safety and tolerability as well as the pharmacokinetic properties of EP395.

Details
Condition adult acute lymphocytic leukemia
Treatment Placebo, EP395
Clinical Study IdentifierNCT04819854
SponsorEpiEndo Pharmaceuticals
Last Modified on6 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject's written informed consent obtained prior to any study-related procedures
Able to understand and comply with the requirements of the study, as judged by the investigator or designee
Men and women between 18-65 years inclusive
Female subjects must either be of non-childbearing potential or if of childbearing potential, must not be pregnant or breast feeding and use a highly effective birth control method during treatment and for 90 days following last dose
Male subjects must use highly effective contraception during treatment and for 90 days following last administered dose
Subject must agree not to donate semen or ova/oocytes during the study and for 90 days after the last dose of IMP
Body mass index (BMI) 18 and 32 kg/m2
Subjects with normal hearing
Subjects must be in good health at the time of screening

Exclusion Criteria

History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the subject's safety
History or presence of vestibular disorder including vertigo, dizziness or other auditory impairment as judged by the investigator or designee
After 10 minutes supine rest at the time of screening or prior to dosing, any vital signs values outside the following ranges
Systolic blood pressure <90 or >150 mmHg, or
Diastolic blood pressure <50 or >95 mmHg, or
Pulse <40 or >90 bpm
Any clinically significant abnormalities in resting ECG at the time of screening or pre-dose Day 1 including prolonged QTcF (>450 ms for males; >470 ms for females) and cardiac arrhythmias, as judged by the Investigator or designee
Clinically significant abnormalities in renal function
serum creatinine >ULN
eGFR <60 mL/min or 60mL/min with evidence of any kidney dysfunction (e.g. proteinuria, or clinical findings as judged by the investigator)
Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP (Day 1)
Malignancy within the past five years with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps
Any planned major surgery within the duration of the study
History of latent or active tuberculosis or a positive Quantiferon test at screening
Females who are pregnant, breast feeding or plan to be pregnant during the study period or 90 days after
Female subjects with a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and within 24 h prior to the first administration of IMP
Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or 2 antibodies at screening
Positive PCR test for active COVID -19 tested within seven days prior to administration of the IMP on Day 1
History of any drug and/or alcohol abuse in the past two years prior to screening
Regular alcohol consumption in males >21 units per week and females >14 units per week
Positive urine drugs of abuse test and/or alcohol breath test at screening or on admission to the unit prior to administration of the IMP on Day -1 that cannot be accounted for by concomitant medication in the opinion of the Investigator or designee
Current or previous use of tobacco, nicotine products or e-cigarettes in the past six months
Smoking history of > 5 pack years
Positive urine cotinine test at screening or Day -1
Use of any prescribed or non-prescribed medication including analgesics, herbal remedies, vitamins and minerals within two weeks prior to the (first) administration of IMP, except those listed below, at the discretion of the Investigator or designee
hormone replacement therapy (HRT)
hormonal contraception
occasional intake of paracetamol (maximum 2000 mg/day for 3 consecutive days)
nasal decongestants without cortisone for a maximum of 10 days
antihistamines for a maximum of 10 days
anticholinergics for a maximum of 10 days
Use of antacids, PPIs or any medication that changes gastric pH within two weeks prior to the first administration of IMP (Day 1)
Use of macrolide antibiotics within two weeks prior to the first administration of IMP (Day 1)
Subjects who have received a live vaccine in the 28 days prior to Day 1
Plasma donation within one month of screening or blood donation (or corresponding blood loss) 400mL during the three months prior to screening
Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or designee at screen
Subject has dietary restrictions incompatible with the diet that can be provided by the study site, in the opinion of the Investigator or is unwilling to refrain from consuming restricted foods and beverages during the study
Regular excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages
Known history of intolerance or hypersensitivity to macrolides, EP395 or to any other component of the formulation
Known history of intolerance to lactose
Clinically significant serious adverse reaction, allergy or serious hypersensitivity, including to any drug or food, as judged by the Investigator or designee
Involvement in the planning and conduct of the study (applies to all EpiEndo, CRO or investigational site staff)
Participation in another clinical study with an experimental drug within three months or 5 half-lives, whichever is shorter, before the administration of IMP
Considered unsuitable for entry into the study in any other way at the discretion of the principal investigator or designee, e.g. investigator considers the subject unlikely to comply with study procedures, restrictions and requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note